hotspot -WSS

hotspot

author：hotspot 2025-08-26 10:55:40 - browse：8522

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Will General Catalyst be the first of many hospital takeovers?

Wikipedia

WSS

Sanofi CEO defends move to abandon profit guidance, boost research

Sanofi CEO defends move to abandon profit guidance, boost research

Can U.S. cancer drug shortages be fixed?

Vivek Ramaswamy made waves in the debate, much as in biotech

A clever new way to fix Medicaid and graduate medical education

Excited delirium, Elijah McClain, and emergency physicians

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In Memoriam: Notable people who died in 2023

The Sacklers, horror, and ‘The Fall of the House of Usher’

Trump demands the U.S. pay no more for drugs than other countries … again

FDA advisory panel to debate high blood pressure devices

Sports medicine is finally prioritizing gender equality

Abortion policy in the spotlight at Republican debate

Apple is now the first public company to be valued at $3 trillion

Roche's accidental data boosts hopes for anti

Supreme Court strikes down use of affirmative action

Ambulance rides for just $100? Advisers want major billing fixes

focus

Victims of gun violence feel impacts long after bullet wound

FDA advisory panel to debate high blood pressure devices

How the first Native Hawaiian psychiatrist helped diversify medicine

Can U.S. cancer drug shortages be fixed?

Study: New antibiotic targets gonorrhea as well as last existing drug

FDA approves potent Eli Lilly obesity drug, Zepbound

Wikipedia

entertainment

leisure time

explore